The Multinational Association for Supportive Care in Cancer Risk Index: A Multinational Scoring System for Identifying Low-Risk Febrile Neutropenic Cancer Patients
Top Cited Papers
- 16 August 2000
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 18 (16), 3038-3051
- https://doi.org/10.1200/jco.2000.18.16.3038
Abstract
PURPOSE: Febrile neutropenia remains a potentially life-threatening complication of anticancer chemotherapy, but some patients are at low risk for serious medical complications. The purpose of this study was to develop an internationally validated scoring system to identify these patients. MATERIALS AND METHODS: Febrile neutropenic cancer patients were observed in a prospective multinational study. Independent factors assessable at fever onset, predicting low risk of complications, on a randomly selected derivation set, were assigned integer weights to develop a risk-index score, which was subsequently tested on a validation set. RESULTS: On the derivation set (756 patients), predictive factors were a burden of illness indicating absence of symptoms or mild symptoms (weight, 5; odds ratio [OR], 8.21; 95% confidence interval [CI], 4.15 to 16.38) or moderate symptoms (weight, 3; OR, 3.70; 95% CI, 2.18 to 6.29); absence of hypotension (weight, 5; OR, 7.62; 95% CI, 2.91 to 19.89); absence of chronic obstructi...Keywords
This publication has 37 references indexed in Scilit:
- Early Infection in Bone Marrow Transplantation: Quantitative Study of Clinical Factors That Affect RiskClinical Infectious Diseases, 1999
- Outcomes of Bacteremia in Patients with Cancer and Neutropenia: Observations from Two Decades of Epidemiological and Clinical TrialsClinical Infectious Diseases, 1997
- The identification of febrile, neutropenic children with neoplastic disease at low risk for bacteremia and complications of sepsisCancer, 1996
- Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of CancerAntimicrobial Agents and Chemotherapy, 1995
- Factors associated with bacteraemia in febrile, granulocytopenic cancer patientsEuropean Journal Of Cancer, 1994
- Home treatment of febrile neutropenia: An empirical oral antibiotic regimenAnnals of Oncology, 1991
- Early hospital discharge of children with cancer treated for fever and neutropenia: identification and management of the low-risk patient.Journal of Clinical Oncology, 1990
- From the Infectious Diseases Society of America: Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Unexplained FeverThe Journal of Infectious Diseases, 1990
- Empirical Antimicrobial Therapy for Febrile Granulocytopenic Cancer Patients: Lessons from Four EORTC TrialsPublished by Springer Nature ,1988
- Quantitative Relationships Between Circulating Leukocytes and Infection in Patients with Acute LeukemiaAnnals of Internal Medicine, 1966